Mostrar el registro sencillo del ítem
Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BEZIN, Julien
ORCID: 0000-0002-2568-1928 IDREF: 181595710 | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BENARD, Anne | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | HUCTEAU, Emilie
ORCID: 0000-0002-9575-7449 | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | TOURNIER, Marie | |
| dc.contributor.author | MONTASTRUC, Francois | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PARIENTE, Antoine | |
| dc.contributor.author | FAILLIE, Jean-Luc | |
| dc.date.accessioned | 2025-04-10T15:23:47Z | |
| dc.date.available | 2025-04-10T15:23:47Z | |
| dc.date.issued | 2025-02-01 | |
| dc.identifier.issn | 2589-5370 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/206100 | |
| dc.description.abstractEn | BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are extensively evaluated for the risk of suicidal behaviors or ideation; the influence of psychiatric history or obesity on this potential effect remains to be investigated. Therefore, we aimed to assess the association between GLP-1 RA and suicide or suicide attempt, considering these factors. METHODS: Patients ≥18 y who died by suicide or were hospitalized for suicide attempt (2013-2021) with at least one GLP-1 RA dispensing within the 180 preceding days were selected from the French National Health Data System (SNDS). A case-time-control design compared, for each patient, GLP-1 RA exposure in the 30 days preceding the outcome (composite of suicide or suicide attempt) to three earlier 30-day reference periods. Potential exposure trend bias was controlled using up to five time-controls matched on age, sex, psychiatric history, obesity, calendar time. Analyses were adjusted for time-varying confounders. Finally dipeptidyl peptidase-4 (DPP-4) inhibitors were studied as negative controls for potential biases. FINDINGS: This study included 1102 cases and 5494 controls. Mean case age was 57.4 years (SD 11.4); 44.6% were male, 67.6% had a recent psychiatric history and 51.3% had obesity. GLP-1 RA use was not associated with an increased risk of suicide or suicide attempt (OR, 0.62; 95% CI, 0.51-0.75), with consistent results for DPP-4 inhibitors (0.75; 0.67-0.84). Results obtained according to recent psychiatric history and obesity were comparable. INTERPRETATION: This large nationwide case-time-control study provides reassurance about the short-term psychiatric safety of GLP-1 RA, showing no specific risk for patients with psychiatric disorders or obesity. FUNDING: French Medicines Agency. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Dipeptidyl peptidase-4 inhibitors | |
| dc.subject.en | Glucagon-like peptide-1 receptor agonists | |
| dc.subject.en | Reimbursement healthcare databases | |
| dc.subject.en | Self-controlled study | |
| dc.subject.en | Suicide and suicide attempt | |
| dc.title.en | Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study | |
| dc.title.alternative | EClinicalMedicine | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.eclinm.2024.103029 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 39844933 | en_US |
| bordeaux.journal | EClinicalMedicine | en_US |
| bordeaux.page | 103029 | en_US |
| bordeaux.volume | 80 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.team | LEHA_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-05029796 | |
| hal.version | 1 | |
| hal.date.transferred | 2025-04-10T15:23:50Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=EClinicalMedicine&rft.date=2025-02-01&rft.volume=80&rft.spage=103029&rft.epage=103029&rft.eissn=2589-5370&rft.issn=2589-5370&rft.au=BEZIN,%20Julien&BENARD,%20Anne&HUCTEAU,%20Emilie&TOURNIER,%20Marie&MONTASTRUC,%20Francois&rft.genre=article |